Arrowhead's gene-silencing therapy shows strong results in two late-stage triglyceride trials

Arrowhead Pharmaceuticals reported positive data from its lipid-lowering gene-silencing candidate Redemplo in two late-stage studies.

The results suggest the therapy effectively reduces triglyceride levels, positioning it as a potential competitor to Ionis' similar approach.

If the findings are confirmed, the drug could be evaluated in a broader patient population beyond the current indications.

The data were presented on Wednesday, highlighting Arrowhead's progress in the gene-silencing space.